A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(7 sites)

China

Beijing, Beijing, Beijing Municipality

Guangzhou, Guangzhou, Guangdong

Zhengzhou, Zhengzhou, Henan

Changchun, Changchun, Jilin

Shenyang, Shenyang, Liaoning